Antibody‐Incorporated Nanomedicines for Cancer Therapy

Antibody‐based cancer therapy, one of the most significant therapeutic strategies, has achieved considerable success and progress over the past decades. Nevertheless, obstacles including limited tumor penetration, short circulation half‐lives, undesired immunogenicity, and off‐target side effects re...

Full description

Saved in:
Bibliographic Details
Published in:Advanced materials (Weinheim) 2022-06, Vol.34 (24), p.e2109210-n/a
Main Authors: Wu, Shun‐Yu, Wu, Fu‐Gen, Chen, Xiaoyuan
Format: Article
Language:English
Subjects:
Antibodies
antibody‐containing nanodrugs
Anticancer properties
Antigens
Barriers
cancer immunotherapy
cancer theranostics
Cancer therapies
functionalization strategy
monoclonal antibody
Side effects
synergistic cancer therapy
targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody‐based cancer therapy, one of the most significant therapeutic strategies, has achieved considerable success and progress over the past decades. Nevertheless, obstacles including limited tumor penetration, short circulation half‐lives, undesired immunogenicity, and off‐target side effects remain to be overcome for the antibody‐based cancer treatment. Owing to the rapid development of nanotechnology, antibody‐containing nanomedicines that have been extensively explored to overcome these obstacles have already demonstrated enhanced anticancer efficacy and clinical translation potential. This review intends to offer an overview of the advancements of antibody‐incorporated nanoparticulate systems in cancer treatment, together with the nontrivial challenges faced by these next‐generation nanomedicines. Diverse strategies of antibody immobilization, formats of antibodies, types of cancer‐associated antigens, and anticancer mechanisms of antibody‐containing nanomedicines are provided and discussed in this review, with an emphasis on the latest applications. The current limitations and future research directions on antibody‐containing nanomedicines are also discussed from different perspectives to provide new insights into the construction of anticancer nanomedicines. A comprehensive review on the advancements of antibody‐incorporated nanomedicines for cancer therapy is offered. Diverse functionalization strategies, antibody formats, and cancer‐associated antigens are introduced and discussed, with an emphasis on their latest applications in antibody‐incorporated nanotherapeutics. The current limitations and future research directions on antibody‐containing nanomedicines are also proposed.
ISSN:0935-9648
1521-4095
DOI:10.1002/adma.202109210